Lyell Immunopharma Statistics
Share Statistics
Lyell Immunopharma has 295.34M
shares outstanding. The number of shares has increased by 15.8%
in one year.
| Shares Outstanding | 295.34M |
| Shares Change (YoY) | 15.8% |
| Shares Change (QoQ) | 1.05% |
| Owned by Institutions (%) | 58.63% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,374 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 5.66M, so 1.92% of the outstanding
shares have been sold short.
| Short Interest | 5.66M |
| Short % of Shares Out | 1.92% |
| Short % of Float | 2.53% |
| Short Ratio (days to cover) | 8.32 |
Valuation Ratios
The PE ratio is -0.49 and the forward
PE ratio is -0.66.
Lyell Immunopharma's PEG ratio is
-0.01.
| PE Ratio | -0.49 |
| Forward PE | -0.66 |
| PS Ratio | 2743.4 |
| Forward PS | 2257.1 |
| PB Ratio | 0.44 |
| P/FCF Ratio | -1.03 |
| PEG Ratio | -0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Lyell Immunopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.06,
with a Debt / Equity ratio of 0.15.
| Current Ratio | 7.06 |
| Quick Ratio | 7.06 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | -0.29 |
| Debt / FCF | -0.36 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $203.33 |
| Profits Per Employee | $-1,143,313.33 |
| Employee Count | 300 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -83.86% in the
last 52 weeks. The beta is -0.26, so Lyell Immunopharma's
price volatility has been lower than the market average.
| Beta | -0.26 |
| 52-Week Price Change | -83.86% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 40 |
| Average Volume (20 Days) | 907,467 |
Income Statement
In the last 12 months, Lyell Immunopharma had revenue of 61K
and earned -342.99M
in profits. Earnings per share was -1.31.
| Revenue | 61K |
| Gross Profit | 61K |
| Operating Income | -358.75M |
| Net Income | -342.99M |
| EBITDA | -200.64M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.31 |
Full Income StatementBalance Sheet
The company has 105.6M in cash and 58.97M in
debt, giving a net cash position of 46.63M.
| Cash & Cash Equivalents | 105.6M |
| Total Debt | 58.97M |
| Net Cash | 46.63M |
| Retained Earnings | -1.35B |
| Total Assets | 490.86M |
| Working Capital | 325.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -162.39M
and capital expenditures -464K, giving a free cash flow of -162.86M.
| Operating Cash Flow | -162.39M |
| Capital Expenditures | -464K |
| Free Cash Flow | -162.86M |
| FCF Per Share | -0.62 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -588122.95% and -562285.25%.
| Gross Margin | 100% |
| Operating Margin | -588122.95% |
| Pretax Margin | -562285.25% |
| Profit Margin | -562285.25% |
| EBITDA Margin | -328922.95% |
| EBIT Margin | -588122.95% |
| FCF Margin | -266980.33% |
